Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
Ankle-Brachial Index (ABI) compares ankle systolic pressure to brachial systolic pressure. It is a simple non-invasive vascular screening metric used to identify probable peripheral artery disease and stratify ischemic severity patterns.
Formula: ABI = ankle systolic pressure / brachial systolic pressure.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Patient should rest supine for 5-10 minutes. Using a hand-held Doppler probe (8-10 MHz) and blood pressure cuff, measure systolic blood pressure at four locations: both brachial arteries (arms), and both posterior tibial and dorsalis pedis arteries at the ankles. Record all six systolic values. A standard automatic blood pressure cuff alone is significantly less accurate and should not substitute for hand-held Doppler.
For each leg, ABI = highest ankle pressure (whichever is greater: posterior tibial or dorsalis pedis) divided by the highest brachial pressure (either arm). Calculate separately for the right leg and left leg. Example: right ankle highest = 110 mmHg, highest brachial = 130 mmHg: right ABI = 110/130 = 0.85 (mild PAD). The lower ABI of the two legs determines overall PAD severity.
Normal ABI 1.0-1.4. Borderline 0.91-0.99 (possible early PAD, re-evaluate with exercise ABI). Mild PAD 0.71-0.90. Moderate PAD 0.41-0.70. Severe PAD ≤0.40 (critical limb ischemia, limb threat). ABI >1.4: non-compressible arteries (calcification — common in diabetes, CKD, elderly) — falsely elevated, use toe-brachial index (TBI) instead. An abnormal ABI in any category warrants referral for vascular assessment and intensified cardiovascular risk factor management.
Vascular surgeons, cardiologists, primary care physicians, podiatrists
ABI <0.9 is diagnostic for PAD with sensitivity 79% and specificity 96% versus arteriography (Fowkes et al.). ABI provides a non-invasive, office-based screening test to confirm PAD in patients with claudication, atypical leg symptoms, non-healing wounds, or abnormal vascular exam findings.
Cardiologists, preventive medicine physicians, primary care physicians
ABI <0.9 is a major atherosclerotic cardiovascular disease (ASCVD) risk-enhancing factor per ACC/AHA 2019 Cholesterol Guidelines (Grundy et al., Circulation 2019). Abnormal ABI predicts 2-4 times increased risk of MI and stroke. It should intensify statin therapy and blood pressure management decisions in intermediate-risk patients.
Primary care physicians, diabetes care teams, vascular clinics
ABI screening is recommended for: patients aged >50 with diabetes or smoking history; patients aged >70 regardless of symptoms; patients with exertional leg symptoms or non-healing foot wounds. Early PAD detection prevents limb loss and identifies patients who need aggressive cardiovascular risk factor management.
Vascular surgeons, interventional cardiologists, vascular medicine physicians
Serial ABI measurements track disease progression over time and monitor response to interventions (angioplasty, bypass surgery, supervised exercise programs). Post-procedure ABI improvement confirms successful revascularization. Declining ABI over time documents progressive disease requiring escalation of medical or interventional therapy.
Vascular surgeons, emergency physicians, wound care specialists
ABI quantifies ischemia severity in patients with claudication or rest pain. Claudication typically occurs at ABI 0.5-0.8; critical limb ischemia (rest pain, non-healing ulcers, gangrene) at ABI <0.4. This grading guides urgency of revascularization — critical limb ischemia requires urgent intervention to prevent amputation.
ABI requires a hand-held Doppler probe (8-10 MHz) to detect ankle systolic pressures accurately. Standard automatic blood pressure cuffs significantly overestimate ankle pressures in atherosclerotic vessels and underperform in calcified arteries. The Doppler technique allows the examiner to identify the disappearance and return of Doppler signal precisely, providing accurate systolic pressure measurement even in diseased vessels.
An ABI <0.9 in either leg diagnoses PAD with high specificity (96%) versus digital subtraction arteriography as the gold standard (Fowkes et al., Int Angiol 1992). Sensitivity of 79% means ~21% of PAD patients may be missed by resting ABI (particularly those with single-vessel disease or mild PAD). Positive ABI findings should prompt immediate PAD management. Negative ABI in a symptomatic patient should prompt exercise ABI testing.
An ABI >1.4 indicates medial artery calcification — stiff, non-compressible arteries that maintain high pressure despite luminal narrowing. This pattern is common in diabetes, CKD, and elderly patients. ABI >1.4 is falsely reassuring and does NOT exclude PAD. These patients require toe-brachial index (TBI) using toe cuffs, since digital arteries are less affected by medial calcification. A TBI <0.7 indicates significant PAD in this setting.
ABI <0.9 predicts 2-4 times increased cardiovascular event risk (MI, stroke, CV death). Per ACC/AHA 2019 Cholesterol Guidelines, ABI <0.9 is a major risk-enhancing factor for statin therapy decisions in intermediate-risk patients (7.5-20% 10-year ASCVD risk). Abnormal ABI should intensify LDL lowering (target LDL <70 mg/dL or <55 mg/dL in very high risk), blood pressure control, smoking cessation, and diabetes management.
Some patients with PAD have near-normal resting ABI but develop ischemia with exertion (exercise-induced PAD). Exercise treadmill ABI: measure resting ABI, have patient walk on treadmill (3.5 km/h, 12% grade) until claudication or 5 minutes, then immediately remeasure ankle pressures. A >20% drop in ABI post-exercise versus baseline is diagnostic for hemodynamically significant PAD. This test is particularly valuable for patients with atypical symptoms.
PAD is a powerful marker of systemic atherosclerosis — not just peripheral disease. Patients with PAD have approximately 30% 5-year cardiovascular mortality risk and similar rates of MI and stroke (TASC II Working Group). PAD should be treated as a cardiovascular disease equivalent — the same aggressive secondary prevention as post-MI patients: high-intensity statin, blood pressure control, smoking cessation, antiplatelet therapy, and regular follow-up.
Supervised exercise rehabilitation is the most effective treatment for claudication — improving walking distance by >100% more than cilostazol and more than unsupervised walking (McDermott et al., JAMA 2013; Gardner et al., JAMA 2000). Programs consist of 30-45 minutes of treadmill walking at claudication threshold, 3 times per week, for 12 weeks. It is recommended as a Class I indication in ACC/AHA 2016 PAD Guidelines before considering revascularization for claudication.
Antiplatelet therapy (aspirin 75-325 mg daily OR clopidogrel 75 mg daily) is recommended for symptomatic PAD per ACC/AHA 2016 PAD Guidelines. Clopidogrel has slightly better evidence than aspirin for PAD specifically (CAPRIE trial: 23.8% relative risk reduction vs. aspirin for PAD subgroup). Dual antiplatelet therapy is not standard for stable claudication but is used after PAD intervention. Aspirin alone is reasonable for asymptomatic PAD with ABI <0.9.
Always measure ABI in both legs. PAD may be asymmetric — one leg may have critical ischemia while the other is normal. The lower ABI of the two legs determines overall PAD severity for management decisions. Comparing bilateral ABIs also helps detect mid-aortic occlusive disease (bilateral equal reduction in ABI) vs. unilateral iliac or femoral disease (asymmetric ABI reduction).
Cilostazol 100 mg twice daily is FDA-approved for claudication and improves walking distance by approximately 50-70% in randomized trials. Mechanism: phosphodiesterase III inhibition causes arterial vasodilation and antiplatelet effects. Contraindicated in heart failure with any reduced EF. Alternatives: naftidrofuryl (available in Europe, superior to cilostazol in some meta-analyses). Medical therapy should be combined with supervised exercise, not used as a substitute.
ABI reference ranges and PAD diagnosis: Hirsch et al. (Circulation 2006, ACC/AHA PAD Guidelines). ABI sensitivity 79%, specificity 96% vs. arteriography: Fowkes et al. (Int Angiol 1992). ABI <0.9 predicts 2× MI risk: Fowkes et al. (JAMA 2008, n=400,000 systematic review). ABI as ASCVD risk enhancer: Grundy et al. (Circulation 2019, ACC/AHA Cholesterol Guidelines). Supervised exercise for claudication: Gardner et al. (JAMA 2000), McDermott et al. (JAMA 2013). Cilostazol for claudication: Thompson et al. (Am J Cardiol 2002). ACC/AHA 2016 PAD Guidelines: Gerhard-Herman et al. (JACC 2017). CAPRIE antiplatelet trial in PAD: CAPRIE Steering Committee (Lancet 1996).
Lower ABI values generally indicate worse lower-extremity arterial perfusion and higher PAD likelihood.
Use in suspected claudication, vascular risk assessment, diabetes/smoking populations, and baseline PAD screening workflows.
ABI may be unreliable with arterial calcification (for example, in diabetes or CKD), requiring toe-brachial or duplex-based follow-up.
For related assessments, see ASCVD Risk Calculator, Framingham Risk and Blood Pressure Calculator.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate 10-year ASCVD risk using current 2026 ACC/AHA Pooled Cohort Equations. Statin thresholds: <5% low, 5–7.5% borderline, ≥7.5% intermediate, ≥20% high.
OpenCardiologyCalculate 10-year cardiovascular disease risk with the Framingham Risk Score using age, cholesterol, blood pressure, smoking, and diabetes inputs.
OpenCardiologyClassify blood pressure readings into Normal, Elevated, Stage 1, Stage 2, or Hypertensive Crisis using ACC/AHA thresholds. Includes MAP and pulse pressure.
OpenCardiologyCalculate the Atherogenic Index of Plasma using triglycerides and HDL cholesterol to estimate atherogenic lipid risk.
Open